Nektar Therapeutics is betting heavily on a lead drug that could stand out in common skin and immune conditions, with an upcoming mid-stage study update that may shift how the market views the company. Strong cash on hand and a faster review path help, but setbacks, tough competition, and the risk that this key program disappoints still loom large.Read more
Nektar Therapeutics is betting on its lead drug REZPEG to win in several big autoimmune conditions, but the wait for key results and potential approval could be long. The big question is whether strong early doctor interest can translate into real-world use before rivals and rising trial costs squeeze the company’s runway.Read more
One of Nektar Therapeutics’ experimental immune-system drugs shows early promise in common skin and hair-loss conditions, raising the chance the company breaks out despite years of setbacks. The catch is it still faces a long road through regulators and heavy spending, so the upside comes with real “runway” and funding risks.Read more
No trending discussion available.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
